US Patent

US11541064 — Methods of identifying dosing regimens

Method of Use · Assigned to ZAVANTE THERAPEUTICS Inc · Expires 2039-01-30 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for identifying new dosing regimens for fosfomycin that optimize treatment outcomes and patient safety in mammals.

USPTO Abstract

Methods for identification of new dosing strategies which optimize positive treatment outcomes and patient safety. Specifically, new dosing strategies for fosfomycin and pharmaceutically acceptable salt thereof which have improved treatment outcomes in mammals. For example, a method of treating mammals having a bacterial infection with fosfomycin or a pharmaceutically acceptable salt thereof using improved dosing regimens.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4331 —

Patent Metadata

Patent number
US11541064
Jurisdiction
US
Classification
Method of Use
Expires
2039-01-30
Drug substance claim
No
Drug product claim
No
Assignee
ZAVANTE THERAPEUTICS Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.